These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36210235)

  • 1. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy.
    Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S
    Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric spinal muscular atrophy.
    Dobelmann V; Roos A; Hentschel A; Della Marina A; Leo M; Schmitt LI; Maggi L; Schara-Schmidt U; Hagenacker T; Ruck T; Kölbel H
    J Neurol; 2024 Oct; 271(10):7000-7011. PubMed ID: 39240344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.
    Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R
    Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen.
    Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N
    CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
    Seo G; Kim S; Byun JC; Kwon S; Lee YJ
    Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy.
    Roos A; Schmitt LI; Hansmann C; Hezel S; Salmanian S; Hentschel A; Meyer N; Marina AD; Kölbel H; Kleinschnitz C; Schara-Schmidt U; Leo M; Hagenacker T
    Acta Neuropathol; 2024 Mar; 147(1):53. PubMed ID: 38470509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy.
    Zhang Q; Hong Y; Brusa C; Scoto M; Cornell N; Patel P; Baranello G; Muntoni F; Zhou H
    Sci Rep; 2024 Oct; 14(1):23491. PubMed ID: 39379509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
    Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
    Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen.
    Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C
    J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment for spinal muscular atrophy type I.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
    Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
    J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
    Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
    Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months.
    De Wel B; De Schaepdryver M; Poesen K; Claeys KG
    Ann Clin Transl Neurol; 2022 Aug; 9(8):1241-1251. PubMed ID: 35833245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy.
    Orbach R; Sagi L; Sadot E; Tokatly Latzer I; Shtamler A; Zisberg T; Fattal-Valevski A
    Muscle Nerve; 2022 Dec; 66(6):762-766. PubMed ID: 36214191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in pNFH Levels in Cerebrospinal Fluid and Motor Evolution after the Loading Dose with Nusinersen in Different Types of Spinal Muscular Atrophy.
    Badina M; Bejan GC; Sporea C; Padure L; Mirea A; Leanca MC; Axente M; Grigoras FP; Bejan M; Shelby ES; Neagu E; Ion DA
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512056
    [No Abstract]   [Full Text] [Related]  

  • 20. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
    Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
    J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.